Ind-Swift Laboratories Limited
Registered Office
SCO 850, Shivalik Enclave,
NAC Manimajra, Sector 13,
Chandigarh – 160101 INDIA
info@indswiftlabs.com
0172-2730503, 2730920, 5061851-53
CIN No. L24232CH1995PLC015553

Ref: ISLL:CH:2026 **Date: 12th August, 2026**

The President
Corporate Relationship Department
BSE Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai 400 001

The Vice President,
Listing Compliance Department,
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor
Plot No. C/2, G-Block,
Bandra Kurla Complex, Bandra (E),
Mumbai 400 051

BSE Scrip Code: 532305

NSE Symbol: INDSWFTLAB

SUBJECT: PRESS RELEASE

Dear Sir/Ma'am,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, kindly find enclosed herewith a Press Release on the Latest Quarterly Results for the Quarter ended 30th June, 2026.

Kindly take the above information on record.

Thanking you,
For **IND-SWIFT LABORATORIES LTD.**

PARDEEP VERMA
Digitally signed by PARDEEP VERMA
Date: 2026.08.12 14:38:30 +05'30'

Ind-Swift Laboratories Ltd. CHANDIGARH

PARDEEP VERMA
VP-CORPORATE AFFAIRS &
COMPANY SECRETARY
Encl: a/a

PRESS RELEASE

Ind-Swift Laboratories Reports Robust Q1 FY27 Results; Op. EBITDA up 2.85x YoY, PAT up 2.04x YoY, Op. EBITDA Margin Expands 1,258 BPS

Chandigarh, August 12th, 2026 - Ind-Swift Laboratories Limited (BSE: 532305 | NSE: INDSWFTLAB), a leading pharmaceutical formulations company with a presence across 85+ countries, announced its un-audited standalone financial results for the quarter ended June 30, 2026 (Q1 FY27), reporting strong growth in profitability and margins.

During the quarter, the Company continued to strengthen its position as a focused, debt-free formulations platform, supported by growing international operations and continued expansion across regulated and emerging markets. A key milestone was the commercialization of the Viatris (USA), Manx (UK) and Arrotex (Australia) CDMO partnership, expected to contribute an incremental ₹200-220 crore of revenue in FY27. The quarter also saw two products reach commercialization, Ibuprofen Sachet for the European market and Macrogol Sachet for the UK and Australia markets. The Company's global dossier pipeline continued to expand as well, with dossiers filed rising to 2,100+ from 1,915+ earlier and product registrations growing to 900+ from 750+. Alongside this, the Company continues to progress the planned upgrade of its Samba manufacturing facility to EU-GMP and PIC/S standards, expected to enhance export capabilities, support filings across regulated markets and strengthen long-term growth visibility.

Standalone Key Financial Highlights:

Particulars (₹ Crs.)	Q1 FY27	Q1 FY26	Y-o-Y Change (%)
Operating Income	**186.08**	153.58	⬆ 21.16
Op. EBITDA	**33.32**	8.66	⬆ 2.85x
Op. EBITDA (%)	**17.91**	5.33	⬆ 1258.11 BPS
PAT - exc exceptional items	**24.68**	8.12	⬆ 2.04x
PAT Margin (%)	**13.26**	4.99	⬆ 826.85 BPS

Management Commentary

Mr. N.R. Munjal, Chairman of Ind-Swift Laboratories, further stated, “Q1 FY27 has been an excellent start to the year for Ind-Swift Laboratories, as we continue to build on our transformation from an API player into a focused FDF manufacturer. The Company delivered a strong quarter, with **operating EBITDA improving 2.85x YoY to ₹33.32 crore and op. EBITDA margin expanding by 1,258 bps YoY to 17.91%**. PAT (excluding exceptional items) stood at **₹24.68 crore, a 2.04x YoY jump**, while PAT margin **improved by 827 bps YoY to 13.26%.**

Ind-Swift Laboratories Limited
Registered Office
SCO 850, Shivalik Enclave,
NAC Manimajra, Sector 13,
Chandigarh – 160101 INDIA
info@indswiftlabs.com
0172-2730503, 2730920, 5061851-53
CIN No. L24232CH1995PLC015553

reflecting better efficiencies, an improved business mix and disciplined execution across the organization.

Over the past two years, we have successfully transformed Ind-Swift into a debt-free, pure-play formulations platform with a strong global footprint spanning **85+ countries**, supported by over **900 product registrations, 2,100+ dossiers filed and 520+ approvals globally**. This transformation has strengthened our balance sheet, sharpened our strategic focus and positioned the Company for scalable, capital-efficient growth.

A key growth initiative currently underway is the planned **upgrade of our Samba manufacturing facility** to EU-GMP and PIC/S standards. This investment is expected to strengthen our regulated-market platform, support filings for molecules across key global markets, enhance export opportunities and expand our participation in high-value CDMO programs, while improving manufacturing efficiency and operational scalability.

Looking ahead, on the domestic side we are focused on expanding our ethical footprint into peninsular India and into high-growth chronic therapeutic categories, targeting **15-20% CAGR growth** in this business. Internationally, our priorities remain own-brand growth. Supported by our growing export pipeline, deeper own-brand penetration in UAE, Central Asia and the rest of the world, the now-commercialized Viatris partnership and other upcoming programs with global partners, and expanding dossier portfolio and continued investment in compliant manufacturing infrastructure, we expect FY27 to witness **revenue growth of more than 50%**. Beyond this, we remain confident of achieving a **revenue CAGR of 20-25% over the medium term**, alongside EBITDA margin expansion of 600-800 bps driven by an improved business mix and operating leverage."

Industry Overview & Tailwinds

Expanding Global Generics Market: Rising demand for affordable healthcare, increasing generic adoption and upcoming patent expiries continue to create growth opportunities across regulated and emerging markets.

Growing Outsourcing & CDMO Opportunities: Global pharmaceutical companies are increasingly outsourcing manufacturing and product development to compliant, cost-efficient partners, benefiting established formulation players with strong regulatory and manufacturing capabilities.

About Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited is a global pharmaceutical company focused on finished dosage formulations, serving regulated and emerging markets through a diversified model spanning international exports, domestic branded formulations, and contract development & manufacturing partnerships.

Company operates manufacturing facilities with multiple international regulatory

Ind-Swift Laboratories Limited
Registered Office
SCO 850, Shivalik Enclave,
NAC Manimajra, Sector 13,
Chandigarh – 160101 INDIA
info@indswiftlabs.com
0172-2730503, 2730920, 5061851-53
CIN No. L24232CH1995PLC015553

accreditations and is supported by a dedicated formulation R&D infrastructure, enabling product development, filings, and commercialization across key therapeutic segments and geographies.

Post its strategic restructuring and API & CRAMS divestment, Ind-Swift operates as a net-debt-free, pure-play formulations platform with a strong, capital-efficient balance sheet. Backed by a robust dossier pipeline, established partnerships, and broad international presence, the Company is focused on expanding exports, strengthening CDMO visibility, and delivering sustainable growth with improving margins.

Disclaimer

This document contains forward-looking statements, which are not historical facts and are subject to risks and uncertainties such as government actions, local developments, and technological risks. The Company is not responsible for any actions taken based on these statements and does not commit to publicly updating them to reflect future events or circumstances.

For further Info Please contact

Pardeep Verma VP-Corporate Affairs and Company Secretary +91-9814131627 investor@indswiftlabs.Com	Investor Relations Advisors Confideleap Partners insfo@confideleap.com +(91) 85911 45959 www.confideleap.com